logo
Plus   Neg
Share
Email

Evotec Forms Breakpoint Therapeutics

Evotec SE (EVTCY.PK) said that it formed Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response or "DDR" portfolio.

Breakpoint Therapeutics, which aims to accelerate early projects through discovery and pre-clinical development and expect to deliver the first IND-ready drug in 2022, will initially focus on advancing multiple drug discovery programmes initiated at Evotec that address high unmet medical needs of different patient groups.

The early stage funding amounting to 30 million euros will be covered by a consortium led by Medicxi, Taiho Ventures LLC, and Evotec. Evotec will hold below 50% of the company and consolidate at equity accordingly.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tech giant Apple Inc. (AAPL) is reportedly planning to begin assembling a new low-cost iPhone 9 in February. According to Bloomberg, the Cupertino, California-based company is expected to officially unveil the new phone as early as March. The assembly work for the new handset will be split among Taiwan-based... A Louisville, Kentucky-based franchise of Wendy's and Fazoli's restaurants, was ordered by the federal government to pay a civil penalty of $157,114 for violating child labor laws. The U.S. Department of Labor's Wage and Hour Division or WHD said its investigation found that Manna Inc. violated child labor requirements of the Fair Labor Standards Act at 99 Wendy's and Fazoli's restaurants. Tesla's market capitalization briefly crept up the $100 billion mark in extended trading on Tuesday, making it the first publicly-listed automaker in the U.S. to achieve the feat. Tesla's stock gained 7.2 percent to close Tuesday's regular trading session at $547.20, and rose to $555 in after-hours trading, pushing the luxury electric car maker's market valuation to more than $100 billion.
Follow RTT
>